A quality improvement project to reduce length of stay for neonatal abstinence syndrome.

BACKGROUND AND OBJECTIVE: Neonatal abstinence syndrome (NAS), a self-limiting condition, is associated with clinical symptoms that may require pharmacological intervention. Optimal treatment of NAS remains undetermined, but the hospital length of stay (LOS) for patients with NAS is partially dependent upon a standard treatment protocol used. Prolonged LOS for patients with NAS can lead to adverse patient harm, impaired maternal-infant attachment, and significant health care costs. Therefore, we conducted a quality improvement study to reduce the LOS for infants with NAS. METHODS: In 2009, a multidisciplinary NAS Taskforce was created to implement a standardized treatment protocol, discuss the strengths and weaknesses of the current medical and nursing management, and improve communication among staff. Infants with NAS that required pharmacological intervention were followed throughout their hospitalization. Readmission within 30 days of hospital discharge was tracked as a balancing measure. RESULTS: Ninety-two infants were eligible for the project including 23 infants from a baseline period (January 2007-August 2009). Reliable monitoring of symptoms and the administration of a standardized morphine protocol effectively reduced LOS from 36 days to 18 days by June 2012. This improvement was sustained through December 2012. No patients were readmitted for NAS treatment. CONCLUSIONS: The most effective interventions that impacted LOS for infants with NAS were the development of a staff NAS education program and the implementation of a standard treatment protocol. The formation of the NAS Taskforce was also essential because it facilitated communication and the dissemination of vital treatment information among all clinical staff.

Neonatal therapeutic hypothermia-associated hypomagnesemia during parenteral nutrition therapy.

BACKGROUND: Hypoxic-ischemic encephalopathy (HIE) is a significant cause of morbidity and mortality in the neonatal population. Total body cooling in term infants who meet the criteria for moderate to severe HIE has been shown to be neuroprotective. A decreased core body temperature is known to affect kinetic properties of many enzyme systems in which magnesium is a cofactor. Maintenance of magnesium during therapeutic hypothermia appears to play an important role in neuroprotection. Currently, there are no studies evaluating the effects that therapeutic hypothermia in neonates has on serum magnesium levels and implications for parenteral nutrition (PN) management. Our hypothesis was that neonatal hypothermia would result in hypomagnesemia and require magnesium therapy. METHODS: Laboratory measurement of serum magnesium was obtained in all infants during the cooling process. RESULTS: Serum magnesium was depressed (<1.6 mg/dL) in 80% of the infants cooled despite administration of standard PN and required additional magnesium supplementation. CONCLUSION: Further studies are needed to determine the target magnesium required for PN in hypothermic therapy.

Blood pressure support in the very low-birth-weight infant during the first week of life.

The immature cardiovascular system of very preterm infants predisposes them to low systemic blood flow during the first week of life, a state that may be damaging to multiple organ systems. There are many treatment strategies for the maintenance of cardiovascular equilibrium in these infants, each with its own advantages and risks. Caregivers are responsible for assessing the circulatory status of each patient and evaluating the effectiveness of interventions aimed at maintaining adequate systemic blood flow. Therefore, it is important to have an understanding of the mechanics of transitional circulation, the relationship between blood pressure and systemic blood flow, and the therapies used to treat infants with compromised organ perfusion.

Safety of ketorolac in surgical neonates and infants 0 to 3 months old.

BACKGROUND: Ketorolac is a nonsteroidal antiinflammatory drug widely used as an adjunct to postoperative pain control in adult and pediatric patients. Minimal safety data exist regarding the use of ketorolac in neonates. METHODS: The charts of 57 postsurgical neonates between 0 and 3 months of age were retrospectively reviewed for bleeding events associated with ketorolac. Data included gestational age (GA), corrected gestational age (CGA) at the time of ketorolac, serum creatinine, platelet count, urine output (in milliliters per kilogram per hour), concomitant medications, enteral feeds, number of ketorolac doses, and surgical procedure performed. RESULTS: Of 57 patients, 10 (17.2%) demonstrated a bleeding event. Mean CGA and serum creatinine for those with bleeding events was 39.4 weeks (P = .69) and 0.64 mg/dL (P = .03), respectively. Patients with a bleeding event received ketorolac at a mean of 20.7 days of life with 70% receiving the drug at less than 14 days of age, whereas those without a bleeding event received ketorolac at a mean of 31.9 days (P = .04). Bleeding events correlated with glomerular filtration rate of less than 30 mL/min/1.73 m(2) or concomitant medications in all but 1 patient. CONCLUSIONS: Infants younger than 21 days and less than 37 weeks CGA are at significantly increased risk for bleeding events and should not be candidates for ketorolac therapy.